WARSAW, Ind.--(BUSINESS WIRE)--Biomet Sports Medicine, LLC, a subsidiary of Biomet, Inc., announced today the launch of the JuggerKnotless Soft Anchor device. The JuggerKnotless Soft Anchor is the latest product offering in the JuggerKnot Soft Anchor family of all-suture implants, securing its position as a leader in all-suture anchor technology.
This product, which may be utilized for labral repair surgery in the shoulder, is the first all-suture, knotless device on the market. Knotless anchor technology, which allows surgeons to secure soft tissue without the use of surgical knots, represents a large and growing segment of the sports medicine shoulder market. By combining all-suture and knotless technologies, Biomet Sports Medicine is creating a new market segment, as it did four years ago with the launch of the JuggerKnot Soft Anchor Device.
“Biomet has a strong and proven tradition of developing state-of-the-art products like the JuggerKnot Soft Anchor,” says Dean Trippiedi, Vice President and General Manager of Biomet Sports Medicine. “The JuggerKnotless builds on this tradition by bringing together Biomet Sports Medicine’s all-suture and adjustable loop technologies to provide surgeons with the unique ability to control the tension of the soft tissue repair. This product is a representation of our continued focus on providing valuable product innovation that supports surgeons and the patients they serve.”
The JuggerKnotless Soft Anchor features:
- The benefits of all-suture anchor technology, which eliminates the use of a hard implant that can fracture and cause loose bodies in the joint.
- A small, 2.1mm drill hole that preserves bone and allows more freedom in anchor placement.
- Unique technology that provides the surgeon with the ability to control the tension of the construct without tying a surgical knot.
The JuggerKnotless Soft Anchor will be featured at Biomet Sports Medicine’s booth #433 at the American Orthopaedic Society for Sports Medicine (AOSSM) Annual Meeting in Seattle, WA July 10-12.
The JuggerKnotless Soft Anchor is cleared for use within the United States only. Distribution outside of the United States is prohibited.
Biomet is a manufacturer of orthopedic implants and does not practice medicine. Only an orthopedic surgeon can determine what treatment is appropriate. Individual results may vary. Potential risks include, but are not limited to, loosening, migration, wear, damage, or failure, any of which may require additional surgery. For additional information on the JuggerKnotless Soft Anchor, including risks and warnings, see the full patient risk information on Biomet.com.
All trademarks herein are the property of Biomet, Inc., or its subsidiaries, unless otherwise indicated.
About Biomet
Biomet, Inc. and its subsidiaries design,
manufacture and market surgical and non-surgical products used primarily
by orthopedic surgeons and other musculoskeletal medical specialists.
Biomet's product portfolio includes hip and knee reconstructive
products; sports medicine, extremities and trauma products; spine, bone
healing and microfixation products; dental reconstructive products; and
cement, biologics and other products. Headquartered in Warsaw, Indiana,
Biomet and its subsidiaries currently distribute products in
approximately 90 countries.
Contact
For further information visit www.biomet.com
or contact Bill Kolter, Vice President, Marketing and Public Affairs, at
(574) 372-1535 or bill.kolter@biomet.com.
Forward-Looking Statements
This press release contains
“forward-looking statements” within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934, as amended. Those statements are often indicated by the use of
words such as “will,” “intend,” “anticipate,” “estimate,” “expect,”
“plan” and similar expressions. Forward-looking statements involve
certain risks and uncertainties. Actual results may differ materially
from those contemplated by the forward looking statements due to, among
others, the following factors: the ability of the LVB Acquisition Inc.
(“LVB”), the parent of Biomet, Inc. (the “Company”), and Zimmer
Holdings, Inc. (“Zimmer”) to complete their proposed merger; LVB’s and
Zimmer’s ability to obtain regulatory approvals of the proposed merger
on the contemplated terms and schedule; the impact of the announcement
of, or failure to complete, the proposed merger on relationships with
distributors, employees, customers and suppliers; the success of the
Company’s principal product lines; the results of the ongoing
investigation by the United States Department of Justice; the ability to
successfully implement new technologies; the Company’s ability to
sustain sales and earnings growth; the Company’s success in achieving
timely approval or clearance of its products with domestic and foreign
regulatory entities; the impact to the business as a result of
compliance with federal, state and foreign governmental regulations and
with the Deferred Prosecution Agreement; the impact to the business as a
result of the economic downturn in both foreign and domestic markets;
the impact of federal health care reform; the impact of anticipated
changes in the musculoskeletal industry and the ability of the Company
to react to and capitalize on those changes; the ability of the Company
to successfully implement its desired organizational changes and
cost-saving initiatives; the ability of the Company to successfully
integrate acquisitions; the impact to the business as a result of the
Company’s significant international operations, including, among others,
with respect to foreign currency fluctuations and the success of the
Company’s transition of certain manufacturing operations to China; the
impact of the Company’s managerial changes; the ability of the Company’s
customers to receive adequate levels of reimbursement from third-party
payors; the Company’s ability to maintain its existing intellectual
property rights and obtain future intellectual property rights; the
impact to the business as a result of cost containment efforts of group
purchasing organizations; the Company’s ability to retain existing
independent sales agents for its products; the impact of product
liability litigation losses; and other factors set forth in the
Company’s filings with the SEC, including the Company’s most recent
annual report on Form 10-K and quarterly reports on Form 10-Q. Although
the Company believes that the assumptions on which the forward-looking
statements contained herein are based are reasonable, any of those
assumptions could prove to be inaccurate given the inherent
uncertainties as to the occurrence or non-occurrence of future events.
There can be no assurance as to the accuracy of forward-looking
statements contained in this press release. The inclusion of a
forward-looking statement herein should not be regarded as a
representation by the Company that the Company’s objectives will be
achieved. The Company undertakes no obligation to update publicly or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise. Accordingly, the reader is
cautioned not to place undue reliance on forward-looking statements
which speak only as of the date on which they were made.